KRAS and cholangiocarcinoma: Cluster 2 contained 89% (eight of nine; p = 4.6e–10) of KRAS wildtype mPDACs as well as the highest proportion of cholangiocarcinoma samples (64%; nine of 14; p = 1.4e–8) compared to all other clusters, further supporting the high transcriptional similarity between KRAS wildtype mPDAC and cholangiocarcinoma.